M
Matthias T. Ehebauer
Researcher at University of Cambridge
Publications - 20
Citations - 1038
Matthias T. Ehebauer is an academic researcher from University of Cambridge. The author has contributed to research in topics: Notch signaling pathway & RAD51. The author has an hindex of 12, co-authored 18 publications receiving 905 citations. Previous affiliations of Matthias T. Ehebauer include European Bioinformatics Institute & University of Pretoria.
Papers
More filters
Journal ArticleDOI
Notch Signaling Pathway
TL;DR: Notch is a receptor that mediates intercellular signaling through a pathway conserved across the metazoa and recruits several proteins that facilitate transcription, among them the coactivator MAM and histone acetylases.
Journal ArticleDOI
Notch, a Universal Arbiter of Cell Fate Decisions
TL;DR: Although the molecular mechanism of Notch activation is well characterized, further analysis in an appropriate cellular context will provide new insight into Notch signaling.
Journal ArticleDOI
The PE/PPE multigene family codes for virulence factors and is a possible source of mycobacterial antigenic variation: Perhaps more?
TL;DR: The PE/PPE multigene family codes for approximately 10% of the Mycobacterium tuberculosis proteome and is encoded by 176 open reading frames and has a conserved structure and repeat motifs that could be a potential source of antigenic variation in M. tuberculosis.
Journal ArticleDOI
Using a Fragment-Based Approach To Target Protein–Protein Interactions
Duncan Scott,Matthias T. Ehebauer,Matthias T. Ehebauer,Tara L. Pukala,Tara L. Pukala,May Marsh,Tom L. Blundell,Ashok R. Venkitaraman,Chris Abell,Marko Hyvönen +9 more
TL;DR: The fragment‐based approach of targeting the interaction between the tumour suppressor BRCA2 and the recombination enzyme RAD51 makes use of a screening pipeline of biophysical techniques that are expected to be more generally applicable to similar targets.
Journal ArticleDOI
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.
Camilo E. Quevedo,Abimael Cruz-Migoni,Abimael Cruz-Migoni,Nicolas Bery,Ami Miller,Tomoyuki Tanaka,Donna Petch,Carole J. R. Bataille,Lydia Y. W. Lee,Phillip S. Fallon,Hanna Tulmin,Hanna Tulmin,Matthias T. Ehebauer,Matthias T. Ehebauer,Narcis Fernandez-Fuentes,Narcis Fernandez-Fuentes,Angela J. Russell,Stephen B. Carr,Stephen B. Carr,Simon E. V. Phillips,Simon E. V. Phillips,Terence H. Rabbitts +21 more
TL;DR: Small molecules are identified that inhibit RAS-effector interactions and readily penetrate cells and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.